Roman Butler Fullerton & Co. Sells 127 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Roman Butler Fullerton & Co. reduced its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,036 shares of the company’s stock after selling 127 shares during the period. Roman Butler Fullerton & Co.’s holdings in GE HealthCare Technologies were worth $240,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Pathway Financial Advisers LLC purchased a new position in shares of GE HealthCare Technologies in the 1st quarter worth $25,000. BNP Paribas purchased a new position in shares of GE HealthCare Technologies in the 1st quarter worth $30,000. Rise Advisors LLC grew its stake in shares of GE HealthCare Technologies by 241.4% in the 1st quarter. Rise Advisors LLC now owns 338 shares of the company’s stock worth $31,000 after buying an additional 239 shares in the last quarter. Riverview Trust Co purchased a new position in shares of GE HealthCare Technologies in the 1st quarter worth $31,000. Finally, Annapolis Financial Services LLC grew its stake in shares of GE HealthCare Technologies by 171.9% in the 1st quarter. Annapolis Financial Services LLC now owns 348 shares of the company’s stock worth $32,000 after buying an additional 220 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Price Performance

NASDAQ:GEHC traded up $1.80 during trading hours on Tuesday, reaching $84.17. 1,765,834 shares of the company were exchanged, compared to its average volume of 3,094,665. The company has a current ratio of 1.06, a quick ratio of 0.83 and a debt-to-equity ratio of 1.05. The stock’s 50-day moving average is $79.30 and its 200-day moving average is $82.85. The firm has a market cap of $38.42 billion, a PE ratio of 24.08, a price-to-earnings-growth ratio of 3.00 and a beta of 1.17. GE HealthCare Technologies Inc. has a twelve month low of $62.35 and a twelve month high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, July 31st. The company reported $1.00 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.02. The business had revenue of $4.84 billion during the quarter, compared to analysts’ expectations of $4.88 billion. GE HealthCare Technologies had a net margin of 8.10% and a return on equity of 25.26%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.92 earnings per share. On average, sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Friday, July 19th will be issued a $0.03 dividend. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.14%. The ex-dividend date of this dividend is Friday, July 19th. GE HealthCare Technologies’s dividend payout ratio is currently 3.51%.

Insider Activity at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Thomas J. Westrick sold 2,750 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $80.78, for a total transaction of $222,145.00. Following the completion of the transaction, the chief executive officer now owns 17,509 shares of the company’s stock, valued at $1,414,377.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CTO Taha Kass-Hout sold 3,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total value of $259,710.00. Following the completion of the transaction, the chief technology officer now owns 67,300 shares of the company’s stock, valued at $5,296,510. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Thomas J. Westrick sold 2,750 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $80.78, for a total transaction of $222,145.00. Following the completion of the transaction, the chief executive officer now directly owns 17,509 shares of the company’s stock, valued at approximately $1,414,377.02. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,005 shares of company stock valued at $5,941,366. 0.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on GEHC shares. Bank of America dropped their price target on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Mizuho reduced their price objective on shares of GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Stifel Nicolaus began coverage on shares of GE HealthCare Technologies in a research note on Tuesday, August 6th. They set a “buy” rating and a $100.00 price objective for the company. The Goldman Sachs Group began coverage on shares of GE HealthCare Technologies in a research note on Thursday, May 30th. They set a “neutral” rating and a $87.00 price objective for the company. Finally, Redburn Atlantic upgraded shares of GE HealthCare Technologies to a “strong-buy” rating in a research note on Thursday, August 1st. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $94.58.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.